News
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Formycon AG analysis, maintaining BUY rating with increased target price of €49. Company aims for 2025 revenue of €55-65m and improved financial position after new corporate bond issuance -
-
-
COMMUNIQUÉ DE PRESSE
Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
Formycon AG to discuss 2025 half-year results in conference call and attend international investor conferences in the 3rd quarter of 2025. Details and registration info provided -
-
-
COMMUNIQUÉ DE PRESSE
Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
Formycon completes patient enrollment for clinical development of Keytruda biosimilar FYB206. Results expected in Q1 2026. Streamlined program accelerates development -
-